<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2024-3-44-51</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Выживаемость и структура летальных исходов в оренбургской популяции пациентов с системной красной волчанкой</article-title><trans-title-group xml:lang="en"><trans-title>Survival and lethal outcomes in Orenburg population of patients with systemic lupus erythematosus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8090-7064</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лазарева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lazareva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Викторовна Лазарева</p><p>460014, ул. Советская, 6; Оренбург</p></bio><bio xml:lang="en"><p> Natalya Viktorovna Lazareva</p><p>460014; 6, Sovetskaya Street; Orenburg</p></bio><email xlink:type="simple">Okashechka@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9478-8916</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бугрова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bugrova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>460014, ул. Советская, 6; Оренбург</p></bio><bio xml:lang="en"><p>460014; 6, Sovetskaya Street; Orenburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6030-9083</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Артемова</surname><given-names>Н. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Artemova</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>460014, ул. Советская, 6; Оренбург</p></bio><bio xml:lang="en"><p>460014; 6, Sovetskaya Street; Orenburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9224-6643</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нагорнова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nagornova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>191015; ул. Кирочная, 41; Санкт-Петербург</p></bio><bio xml:lang="en"><p>191015; 41, Kirochnaya Street; St. Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Оренбургский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Orenburg State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова»&#13;
Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>14</day><month>06</month><year>2024</year></pub-date><volume>18</volume><issue>3</issue><fpage>44</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лазарева Н.В., Бугрова О.В., Артемова Н.Э., Нагорнова К.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Лазарева Н.В., Бугрова О.В., Артемова Н.Э., Нагорнова К.А.</copyright-holder><copyright-holder xml:lang="en">Lazareva N.V., Bugrova O.V., Artemova N.E., Nagornova K.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1587">https://mrj.ima-press.net/mrj/article/view/1587</self-uri><abstract><p>   В настоящее время прогноз при системной красной волчанке (СКВ) существенно улучшился, однако относительный риск смерти у таких больных по-прежнему выше, чем в популяции в целом. Лидирующие позиции среди причин летальности при СКВ занимают тромботические осложнения.</p><p>   Цель исследования – анализ выживаемости и структуры летальных исходов в оренбургской популяции пациентов с СКВ, в том числе вследствие тромботических осложнений.</p><sec><title>   Материал и методы</title><p>   Материал и методы. Проведено двухэтапное исследование течения СКВ и выживаемости пациентов с 2007 по 2022 гг. У всех больных изначально (n = 68) и у выживших (n = 50) через 15 лет были оценены клинические признаки заболевания. Медиана возраста на момент включения в исследование составила 35 [29; 45] лет, давности болезни – 7,5 [3; 13,5] года. На втором этапе определяли особенности течения болезни у выживших пациентов и причины смерти у умерших за 15 лет.</p><p>   Результаты и обсуждение. 10-, 15-, 20-летняя выживаемость в оренбургской популяции пациентов с СКВ достигала соответственно 98,5; 95,5 и 86,3%. За указанный период было зафиксировано 18 (26,5 %) смертей, медиана возраста умерших составила 48,5 [39; 57] года, давности заболевания – 22 [16; 30] года. Ведущими причинами смерти были тромботические осложнения (n = 14, 78 %) на фоне антифосфолипидного синдрома, волчаночного нефрита, артериальной гипертензии. Реже причиной смерти являлись инфекционные осложнения (n = 4, 22 %). При наличии тромботических осложнений 20-летняя выживаемость составила 80,2 %, что значимо ниже, чем в группе СКВ без тромбозов.</p></sec><sec><title>   Заключение</title><p>   Заключение. Полученные результаты позволяют считать наличие тромботических осложнений у пациентов с СКВ в оренбургской популяции неблагоприятным фактором прогноза.</p></sec></abstract><trans-abstract xml:lang="en"><p>   Currently, the prognosis for systemic lupus erythematosus (SLE) has improved significantly, but the relative risk of death in these patients is stillhigher than in the general population. Thrombotic complications are one of the leading causes of death in SLE.</p><sec><title>   Objective</title><p>   Objective: to analyze the survival rate and structure of lethal outcomes in Orenburg population of patients with SLE, including deaths due to thrombotic complications.</p></sec><sec><title>   Material and methods</title><p>   Material and methods. A two-stage study of SLE progression and patient survival was conducted from 2007 to 2022. Clinical signs of the diseasewere analyzed in all patients at baseline (n = 68) and in survivors (n = 50) after 15 years. The median age at the time of enrolment in the study was 35 [29; 45] years, the disease duration – 7.5 [3; 13.5] years. During the second stage, the characteristics of the course of the disease in the survived patients and the causes of death in those who died over 15-year period were determined.</p><p>   Results and discussion. The 10-, 15- and 20-year survival rates in Orenburg population of patients with SLE reached 98.5, 95.5 and 86.3%, respectively. During this period, 18 (26.5 %) deaths were registered, the median age of the deceased was 48.5 [39; 57] years, and the duration of the disease was 22 [16; 30] years. The most common causes of death were thrombotic complications (n = 14, 78 %) due to antiphospholipid syndrome, lupus nephritis, and arterial hypertension. Less frequently, infectious complications were the cause of death (n = 4, 22 %). Patients with thrombotic complications had a 20-year survival rate of 80.2% that was significantly lower than in the SLE group without thrombosis.</p></sec><sec><title>   Conclusion</title><p>   Conclusion. The results obtained allow to consider the presence of thrombotic complications in patients with SLE in Orenburg population as an unfavorable prognostic factor.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>системная красная волчанка</kwd><kwd>тромботические осложнения</kwd><kwd>факторы риска</kwd><kwd>выживаемость</kwd><kwd>смертность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus</kwd><kwd>thrombotic complications</kwd><kwd>risk factors</kwd><kwd>survival</kwd><kwd>mortality</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The investigation has not been sponsored</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 с.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. Moscow: GEOTAR-Media; 2010. 752 p.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Решетняк ТМ, Соловьев СК, Попкова ТВ. Системная красная волчанка и антифосфолипидный синдром: вчера, сегодня, завтра. Терапевтический архив. 2023;95(5):365-374.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Reshetnyak TM, Solovyev SK, Popkova TV. Systemic lupus erythematosus and antiphospholipid syndrome: past, present, future. Terapevticheskii Arkhiv. 2023;95(5): 365-374. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Клюквина НГ, Насонов ЕЛ. Выживаемость мужчин, страдающих системной красной волчанкой. Научно-практическая ревматология. 2009;47(6):46-51.</mixed-citation><mixed-citation xml:lang="en">Klyukvina NG, Nasonov EL. Survival of men with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2009;47(6):46-51. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев СВ, Новиков ПИ, Буланов НМ. Системная красная волчанка: эпидемиология, отдаленные исходы и бремя болезни. Клиническая фармакология и терапия. 2021;30(4):13-22.</mixed-citation><mixed-citation xml:lang="en">Moiseev SV, Novikov PI, Bulanov NM. Systemic lupus erythematosus: epidemiology, outcomes and burden. Klinicheskaya farmakologiya i terapiya. 2021;30(4):13-22. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Тареева ИЕ, Филимонова РГ, Янушкевич ТН, Куприянова ЛА. Течение и прогноз волчаночного нефрита. Терапевтический архив. 1980;(1):68-72.</mixed-citation><mixed-citation xml:lang="en">Tareeva IE, Filimonova RG, Yanushkevich TN, Kupriyanova LA. The course and prognosis of lupus nephritis. Terapevticheskii Arkhiv. 1980;(1):68-72. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wallace DJ, Rodell T, Weiner J, et al. Systemic lupus erythematosus survival patterns: experience with 609 patients. JAMA. 1981 Mar 6;245(9):934-8. URL: https://pubmed.ncbi.nlm.nih.gov/7463697/.</mixed-citation><mixed-citation xml:lang="en">Wallace DJ, Rodell T, Weiner J, et al. Systemic lupus erythematosus survival patterns: experience with 609 patients. JAMA. 1981 Mar 6;245(9):934-8. URL: https://pubmed.ncbi.nlm.nih.gov/7463697/.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Helve T. Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheumatol. 1985;14(1):43-6. doi: 10.3109/03009748509102015.</mixed-citation><mixed-citation xml:lang="en">Helve T. Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheumatol. 1985;14(1):43-6. doi: 10.3109/03009748509102015.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002 May;61(5):409-13. doi: 10.1136/ard.61.5.409.</mixed-citation><mixed-citation xml:lang="en">Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002 May;61(5):409-13. doi: 10.1136/ard.61.5.409.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med. 1985 Apr;55(216):87-98.</mixed-citation><mixed-citation xml:lang="en">Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med. 1985 Apr;55(216):87-98.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Abu-Shakra M, Urowitz MB, Gladmann DD, Gough J. Mortality studies in systemic lupus erythematosus. Result from a single centre. I Causes of death. J Rheumatol. 1995 Jul;22(7):1259-64.</mixed-citation><mixed-citation xml:lang="en">Abu-Shakra M, Urowitz MB, Gladmann DD, Gough J. Mortality studies in systemic lupus erythematosus. Result from a single centre. I Causes of death. J Rheumatol. 1995 Jul;22(7):1259-64.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Лучихина ЕЛ. Структура летальных исходов при системной красной волчанке по данным Института ревматологии РАМН. Российская ревматология. 1998;(3):2-8.</mixed-citation><mixed-citation xml:lang="en">Luchikhina EL. The structure of deaths in systemic lupus erythematosus according to the Institute of Rheumatology, Russian Academy of Medical Sciences. Rossiiskaya revmatologiya. 1998;(3):2-8. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Cervera R, Khamashta MA, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 2003 Sep;82(5):299-308. doi: 10.1097/01.md.0000091181.93122.55.</mixed-citation><mixed-citation xml:lang="en">Cervera R, Khamashta MA, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 2003 Sep;82(5):299-308. doi: 10.1097/01.md.0000091181.93122.55.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tektonidou MG, Lewandowski LB, Hu J, et al. Survial in adults and children with systemic lupus erythematosus : a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017 Dec;76(12): 2009-2016. doi: 10.1136/annrheumdis-2017-211663. Epub 2017 Aug 9.</mixed-citation><mixed-citation xml:lang="en">Tektonidou MG, Lewandowski LB, Hu J, et al. Survial in adults and children with systemic lupus erythematosus : a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017 Dec;76(12): 2009-2016. doi: 10.1136/annrheumdis-2017-211663. Epub 2017 Aug 9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kang KY, Kwok SK, Ju JH, et al. The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus. 2011 Aug;20(9):989-97. doi: 10.1177/0961203311402245. Epub 2011 Jun 23.</mixed-citation><mixed-citation xml:lang="en">Kang KY, Kwok SK, Ju JH, et al. The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus. 2011 Aug;20(9):989-97. doi: 10.1177/0961203311402245. Epub 2011 Jun 23.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cansu DU, Teke HU, Korkmaz C. Survival Analysis of Turkish Patients with Systemic Lupus Erythematosus: Older Age at Diagnosis Affects Mortality. Arch Rheumatol. 2017 Mar 21;32(2):141-148. doi: 10.5606/ArchRheumatol.2017.6173. eCollection 2017 Jun.</mixed-citation><mixed-citation xml:lang="en">Cansu DU, Teke HU, Korkmaz C. Survival Analysis of Turkish Patients with Systemic Lupus Erythematosus: Older Age at Diagnosis Affects Mortality. Arch Rheumatol. 2017 Mar 21;32(2):141-148. doi: 10.5606/ArchRheumatol.2017.6173. eCollection 2017 Jun.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, Li M, Wang Y, et al. Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China. Lupus. 2018 Apr;27(5): 864-869. doi: 10.1177/0961203317751852. Epub 2018 Jan 7.</mixed-citation><mixed-citation xml:lang="en">Wang Z, Li M, Wang Y, et al. Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China. Lupus. 2018 Apr;27(5): 864-869. doi: 10.1177/0961203317751852. Epub 2018 Jan 7.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, Ren L, Li R, et al. Analysis of 20-year survival rate and prognostic indicators of systemic lupus erythematosus. 2019 Jan 15;99(3):178-182 doi: 10.3760/cma.j.issn.0376-2491.2019.03.005</mixed-citation><mixed-citation xml:lang="en">Wang Z, Ren L, Li R, et al. Analysis of 20-year survival rate and prognostic indicators of systemic lupus erythematosus. 2019 Jan 15;99(3):178-182 doi: 10.3760/cma.j.issn.0376-2491.2019.03.005</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Koh JH, Park EK, Lee HN, et al, Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in southeastern areas of South Korea: a multicenter retrospective cohort study. Int J Rheum Dis. 2020 Jan;23(1):92-100. doi: 10.1111/1756-185X.13761. Epub 2019 Dec 4.</mixed-citation><mixed-citation xml:lang="en">Koh JH, Park EK, Lee HN, et al, Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in southeastern areas of South Korea: a multicenter retrospective cohort study. Int J Rheum Dis. 2020 Jan;23(1):92-100. doi: 10.1111/1756-185X.13761. Epub 2019 Dec 4.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lotfy Fayed H, Ibrahim Emara NA, Mohammed RH. Mortality and disease related comorbidities in systemic lupus erythematosus: data from an Egyptian cohort. Lupus. 2022 Apr;31(5):628-636. doi: 10.1177/09612033221081691. Epub 2022 Mar 20.</mixed-citation><mixed-citation xml:lang="en">Lotfy Fayed H, Ibrahim Emara NA, Mohammed RH. Mortality and disease related comorbidities in systemic lupus erythematosus: data from an Egyptian cohort. Lupus. 2022 Apr;31(5):628-636. doi: 10.1177/09612033221081691. Epub 2022 Mar 20.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lai CC, Sun YS, Chen WS, et al. Risk factors for mortality in systemic lupus erythematosus patients: Analysis of adult and pediatric cohorts in Taiwan. J Chin Med Assoc. 2022 Nov 1;85(11):1044-1050. doi: 10.1097/JCMA.0000000000000783. Epub 2022 Nov 2.</mixed-citation><mixed-citation xml:lang="en">Lai CC, Sun YS, Chen WS, et al. Risk factors for mortality in systemic lupus erythematosus patients: Analysis of adult and pediatric cohorts in Taiwan. J Chin Med Assoc. 2022 Nov 1;85(11):1044-1050. doi: 10.1097/JCMA.0000000000000783. Epub 2022 Nov 2.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Barber M, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021 Sep; 17(9):515-532. doi: 10.1038/s41584-021-00668-1. Epub 2021 Aug 3.</mixed-citation><mixed-citation xml:lang="en">Barber M, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021 Sep; 17(9):515-532. doi: 10.1038/s41584-021-00668-1. Epub 2021 Aug 3.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34. doi: 10.1177/0961203315627202. Epub 2016 Jan 24.</mixed-citation><mixed-citation xml:lang="en">Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34. doi: 10.1177/0961203315627202. Epub 2016 Jan 24.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Исмагилова РР, Заманова ЭС, Максудова АН. Выживаемость пациентов с системной красной волчанкой: данные регионального регистра. Научно-практическая ревматология. 2020;58(2):154-159.</mixed-citation><mixed-citation xml:lang="en">Ismagilova RR, Zamanova ES, Maksudova AN. Survival rates in patients with systemic lupus erythematosus: regional registry data. Nauchno-Prakticheskaya Revmatologiya. 2020;58(2):154-159. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mok CC, Tank SSK, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005 Sep;52(9):2774-82. doi: 10.1002/art.21224.</mixed-citation><mixed-citation xml:lang="en">Mok CC, Tank SSK, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005 Sep;52(9):2774-82. doi: 10.1002/art.21224.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sallai KK, Nagy E, Bodo I, et al. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol. 2007 May-Jun;36(3):198-205. doi: 10.1080/03009740601089283.</mixed-citation><mixed-citation xml:lang="en">Sallai KK, Nagy E, Bodo I, et al. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol. 2007 May-Jun;36(3):198-205. doi: 10.1080/03009740601089283.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mok CC, Ho LY, Yu KL, To CH. Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2010 Jun;29(6):599-604. doi: 10.1007/s10067-009-1364-z. Epub 2010 Jan 26.</mixed-citation><mixed-citation xml:lang="en">Mok CC, Ho LY, Yu KL, To CH. Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2010 Jun;29(6):599-604. doi: 10.1007/s10067-009-1364-z. Epub 2010 Jan 26.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lundström E, Gustafsson JT, Jönsen A, et al. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2013 Jun;72(6):1018-25. doi: 10.1136/annrheumdis-2012-201760. Epub 2012 Aug 14.</mixed-citation><mixed-citation xml:lang="en">Lundström E, Gustafsson JT, Jönsen A, et al. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2013 Jun;72(6):1018-25. doi: 10.1136/annrheumdis-2012-201760. Epub 2012 Aug 14.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kaiser R, Barton JL, Chang M, et al. Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. Genes Immun. 2009 Jul;10(5): 495-502. doi: 10.1038/gene.2009.32. Epub 2009 May 7.</mixed-citation><mixed-citation xml:lang="en">Kaiser R, Barton JL, Chang M, et al. Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. Genes Immun. 2009 Jul;10(5): 495-502. doi: 10.1038/gene.2009.32. Epub 2009 May 7.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 Oct;44(10):2331-7. doi: 10.1002/1529-0131(200110)44:10&lt;2331::aid-art395&gt;3.0.co;2-i.</mixed-citation><mixed-citation xml:lang="en">Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 Oct;44(10):2331-7. doi: 10.1002/1529-0131(200110)44:10&lt;2331::aid-art395&gt;3.0.co;2-i.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004 May 15;103(10): 3677-83. doi: 10.1182/blood-2003-09-3198. Epub 2004 Jan 15.</mixed-citation><mixed-citation xml:lang="en">Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004 May 15;103(10): 3677-83. doi: 10.1182/blood-2003-09-3198. Epub 2004 Jan 15.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus: proposed guidelines for risk factor management. Rheumatology (Oxford). 2004 Jan;43(1):7-12. doi: 10.1093/rheumatology/keg436. Epub 2003 Jul 16.</mixed-citation><mixed-citation xml:lang="en">Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus: proposed guidelines for risk factor management. Rheumatology (Oxford). 2004 Jan;43(1):7-12. doi: 10.1093/rheumatology/keg436. Epub 2003 Jul 16.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725. doi: 10.1002/art.1780400928.</mixed-citation><mixed-citation xml:lang="en">Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725. doi: 10.1002/art.1780400928.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; Aug;64(8): 2677-86. doi: 10.1002/art.34473.</mixed-citation><mixed-citation xml:lang="en">Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; Aug;64(8): 2677-86. doi: 10.1002/art.34473.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2): 288-91.</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2): 288-91.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. doi: 10.1002/art.1780390303.</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. doi: 10.1002/art.1780390303.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.</mixed-citation><mixed-citation xml:lang="en">Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. Semin Arthritis Rheum. 2018 Aug;48(1):117-120. doi: 10.1016/j.semarthrit.2017.12.006. Epub 2018 Jan 5.</mixed-citation><mixed-citation xml:lang="en">Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. Semin Arthritis Rheum. 2018 Aug;48(1):117-120. doi: 10.1016/j.semarthrit.2017.12.006. Epub 2018 Jan 5.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Решетняк ТМ, Чельдиева ФА. Классификационные критерии антифосфолипидного синдрома и его некритериальные проявления. Тромбоз, гемостаз и реология. 2021;(4):4-12.</mixed-citation><mixed-citation xml:lang="en">Reshetnyak TM, Cheldieva FA. Classification criteria of antiphospholipid syndrome and its territorial manifestations. Tromboz, gemostaz i reologiya. 2021;(4):4-12. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
